Literature DB >> 18676868

Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons.

Yanlin Jiang1, Chunlu Guo, Michael R Vasko, Mark R Kelley.   

Abstract

Peripheral neuropathy is one of the major side effects of the anticancer drug cisplatin. Although previous work suggests that this neuropathy correlates with formation of DNA adducts in sensory neurons, growing evidence suggests that cisplatin also increases the generation of reactive oxygen species (ROS), which could cause DNA damage. Apurinic/apyrimidinic endonuclease/redox factor-1 (Ape1/Ref-1) is a multifunctional protein involved in DNA base excision repair of oxidative DNA damage and in redox regulation of a number of transcription factors. Therefore, we asked whether altering Ape1 functions would influence cisplatin-induced neurotoxicity. Sensory neurons in culture were exposed to cisplatin for 24 hours and several end points of toxicity were measured, including production of ROS, cell death, apoptosis, and release of the immunoreactive calcitonin gene-related peptide (iCGRP). Reducing expression of Ape1 in neuronal cultures using small interfering RNA (siRNA) enhances cisplatin-induced cell killing, apoptosis, ROS generation, and cisplatin-induced reduction in iCGRP release. Overexpressing wild-type Ape1 attenuates all the toxic effects of cisplatin in cells containing normal endogenous levels of Ape1 and in cells with reduced Ape1 levels after Ape1siRNA treatment. Overexpressing the redox deficient/repair competent C65-Ape1 provides partial rescue, whereas the repair-deficient Ape1 (N226A + R177A) does not protect neurons from cisplatin toxicity. We also observe an increase in phosphorylation of p53 after a decrease in Ape1 levels in sensory neuronal cultures. These results strongly support the notion that Ape1 is a potential translational target such that protecting Ape1 levels and particularly its DNA repair function could reduce peripheral neuropathy in patients undergoing cisplatin treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676868      PMCID: PMC2591093          DOI: 10.1158/0008-5472.CAN-08-1173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Chemotherapy-induced peripheral neuropathy.

Authors:  Stefan Quasthoff; Hans Peter Hartung
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

Review 2.  Why study rod cell death in retinal degenerations and how?

Authors:  C E Remé; C Grimm; F Hafezi; H P Iseli; A Wenzel
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

3.  Evidence that the bifunctional redox factor / AP endonuclease Ref-1 is an anti-apoptotic protein associated with differentiation in the developing retina.

Authors:  L B Chiarini; F G Freitas; H Petrs-Silva; R Linden
Journal:  Cell Death Differ       Date:  2000-03       Impact factor: 15.828

4.  Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo.

Authors:  S J Fischer; E S McDonald; L Gross; A J Windebank
Journal:  Neurobiol Dis       Date:  2001-12       Impact factor: 5.996

5.  Oxidant-mediated increases in redox factor-1 nuclear protein and activator protein-1 DNA binding in asbestos-treated macrophages.

Authors:  Dawn M Flaherty; Martha M Monick; A Brent Carter; Michael W Peterson; Gary W Hunninghake
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

6.  Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.

Authors:  Mikael Rinne; David Caldwell; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

7.  Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.

Authors:  Kesheng Zhao; Guo-Min Zhao; Dunli Wu; Yi Soong; Alex V Birk; Peter W Schiller; Hazel H Szeto
Journal:  J Biol Chem       Date:  2004-06-02       Impact factor: 5.157

8.  Selenomethionine regulation of p53 by a ref1-dependent redox mechanism.

Authors:  Young R Seo; Mark R Kelley; Martin L Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-30       Impact factor: 11.205

9.  DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation.

Authors:  Huey-Lan Huang; Li-Wen Fang; Shu-Ping Lu; Chen-Kung Chou; Tien-Yau Luh; Ming-Zong Lai
Journal:  Oncogene       Date:  2003-11-06       Impact factor: 9.867

10.  Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition.

Authors:  Dong Wang; Meihua Luo; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2004-06       Impact factor: 6.261

View more
  66 in total

Review 1.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

2.  Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1.

Authors:  Mark R Kelley; Meihua Luo; April Reed; Dian Su; Sarah Delaplane; Richard F Borch; Rodney L Nyland; Michael L Gross; Millie M Georgiadis
Journal:  Antioxid Redox Signal       Date:  2011-01-04       Impact factor: 8.401

3.  The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.

Authors:  En Huang; Dianbo Qu; Yi Zhang; Katerina Venderova; M Emdadul Haque; Maxime W C Rousseaux; Ruth S Slack; John M Woulfe; David S Park
Journal:  Nat Cell Biol       Date:  2010-05-16       Impact factor: 28.824

4.  Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Authors:  Ranajoy Chattopadhyay; Soumita Das; Amit K Maiti; Istvan Boldogh; Jingwu Xie; Tapas K Hazra; Kimitoshi Kohno; Sankar Mitra; Kishor K Bhakat
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

5.  SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair.

Authors:  Manchao Zhang; Wuying Du; Scarlett Acklin; Shengkai Jin; Fen Xia
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

6.  Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression.

Authors:  Yanlin Jiang; Shaoyu Zhou; George E Sandusky; Mark R Kelley; Melissa L Fishel
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

7.  Emodin mitigates the oxidative stress induced by cisplatin in osteosarcoma MG63 cells.

Authors:  Li Yan; Rui Hu; Song Tu; Wen-Jun Cheng; Qiong Zheng; Jun-Wen Wang; Wu-Sheng Kan; Yi-Jun Ren
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

8.  Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Mark R Kelley; James H Wikel; Chunlu Guo; Karen E Pollok; Barbara J Bailey; Randy Wireman; Melissa L Fishel; Michael R Vasko
Journal:  J Pharmacol Exp Ther       Date:  2016-09-08       Impact factor: 4.030

9.  Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Authors:  Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Journal:  DNA Repair (Amst)       Date:  2009-10-15

Review 10.  Redox regulation of DNA repair: implications for human health and cancer therapeutic development.

Authors:  Meihua Luo; Hongzhen He; Mark R Kelley; Millie M Georgiadis
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.